Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$5.98 – $13.18
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.90B | $6.43B | $7.22B | $11.68B | $9.37B | $26.85B | $46.68B | $18.54B |
| Cost of revenue | $1.36B | $1.78B | $1.65B | $2.15B | $2.36B | $8.74B | $12.17B | $11.01B |
| Gross profit | $3.54B | $4.65B | $5.57B | $9.53B | $7.01B | $18.11B | $34.50B | $7.53B |
| Gross margin | 72.2% | 72.3% | 77.1% | 81.6% | 74.8% | 67.5% | 73.9% | 40.6% |
| R&D | $0 | $0 | $0 | $0 | $1.65B | $2.92B | $4.00B | $5.03B |
| Operating income | $2.49B | $2.91B | $3.58B | $6.99B | $4.42B | $8.98B | $21.11B | −$4.98B |
| EBITDA | $2.69B | $3.43B | $4.10B | $8.52B | $5.00B | $10.94B | $23.80B | −$2.85B |
| Net income | $1.89B | $2.34B | $2.77B | $4.45B | $3.61B | $7.55B | $15.01B | −$3.75B |
| Net margin | 38.6% | 36.3% | 38.4% | 38.1% | 38.5% | 28.1% | 32.2% | -20.2% |
| EPS (diluted) | 14.56 | 17.79 | 21.33 | 34.26 | 19.81 | 58.14 | 115.68 | -29.80 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $43.5B | $89.31 | $49.34–$139.49 | 1 |
| 2027 | $45.8B | $95.55 | $52.78–$149.24 | 1 |
| 2028 | $50.0B | $109.39 | $60.43–$170.86 | 1 |
| 2029 | $61.5B | $142.51 | $78.72–$222.59 | 1 |
Forward consensus · source: Financial Modeling Prep
PEPTIDREAM INC ORD
No one on the platform currently holds PPTDF.
No tracked institution reports a position in PPTDF as of their last filing.
No one on the platform has traded PPTDF yet.
| $2.0B |
| — |
| NURPFNeuren Pharmaceuticals Limited | $9.27 | +0.00% | $1.2B | — |
| ONTTFOxford Nanopore Technologies plc | $1.66 | +0.00% | $1.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.1× sales vs its 0.1× historical median P/S.
Fair value ≈ $8.46 · price $6.00 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.